AI Article Synopsis
- Rui-Hua Xu conducted the REGOTORI trial, which revealed that a combination of regorafenib and toripalimab enhances the effectiveness and survival rates in patients with refractory metastatic colorectal cancer.
- The trial also identified that high levels of certain biomarkers were linked to poorer responses and survival outcomes.
- In a Q&A, Xu shares insights about his academic path and outlines potential future developments in cancer research.
Article Abstract
Rui-Hua Xu completed the REGOTORI trial that showed a novel combination regimen, regorafenib plus toripalimab, improved the efficacy and survival of refractory metastatic colorectal cancer, and found high-abundance negatively predicted response and survival. In this Q&A, he discusses his academic journey and the future directions of his field.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460953 | PMC |
| http://dx.doi.org/10.1016/j.xcrm.2022.100618 | DOI Listing |
Publication Analysis
Top Keywords
rui-hua rui-hua
4
rui-hua completed
4
completed regotori
4
regotori trial
4
trial novel
4
novel combination
4
combination regimen
4
regimen regorafenib
4
regorafenib toripalimab
4
toripalimab improved
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!